Jack W. Callicutt
2022
In 2022, Jack W. Callicutt earned a total compensation of $566.6K as Chief Financial Officer at Galectin Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
| Bonus | $96,000 |
|---|---|
| Option Awards | $73,940 |
| Salary | $318,508 |
| Other | $78,116 |
| Total | $566,564 |
Callicutt received $318.5K in salary, accounting for 56% of the total pay in 2022.
Callicutt also received $96K in bonus, $73.9K in option awards and $78.1K in other compensation.
Rankings
In 2022, Jack W. Callicutt's compensation ranked 4,151st out of 5,760 executives tracked by ExecPay. In other words, Callicutt earned more than 27.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,151 out of 5,760 | 28th |
Division Manufacturing | 2,346 out of 3,136 | 25th |
Major group Chemicals And Allied Products | 1,139 out of 1,422 | 20th |
Industry group Drugs | 1,069 out of 1,323 | 19th |
Industry Pharmaceutical Preparations | 783 out of 969 | 19th |
Source: SEC filing on October 6, 2023.
Callicutt's colleagues
We found two more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2022.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020